Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.27), $0.01 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.